RE:RE:RE:SeaGen ADC product revenues and valuationsIt's a fairly similar trend for most biotechs that invest in a pipeline over time and eventually get the science right so at least one product crosses the finish line. We're in that same category and will act according to how good the science behind the product actually is. If it's like pre-clinical it will trace SeaGen and Trodelvy. If not, back to the drawing board.
SeaGen had a $250mil mkt cap like THTX in 2005 as they developed their first ADC for Lymphoma. As the trial suceeded it grew to $1bil in 2009 and then up to the $4-5bil level for around 5 years. As the next ADCs came in to view, it grew to $10bil and when those put up good trial numbers it balooned to the current $25-35bil it's been bouncing around in over last few years.
We can only hope for such success! As we are all saying, stay patient --so far all the scientific evidence has shown that it can work, it should work, it is safe, and there has been some early signs of efficacy. They just have to execute the trial and strategically move to the next step in a cancer where they believe success will be most apparent and useful. Only good science will create value like that and THTX's science, for what it's worth, is every bit as solid as what SeaGen was seeing in their early days. In fact, it's a whole lot safet than what they were seeing. We just need that efficacy in a larger group.
Biobob wrote: Interesting... did any of those company trade like a worthless POS before they reached their glory days... was there any anticipation of success from analysts, from trial participants and their relatives.. some word of mouth, from speculators. Are we seing any of this atm, any hopefull signs of success to come...